Skip to content

Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.

Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies. - Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011667
Enrollment
450
Registered
2013-10-01
Start date
2013-12-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric and colon cancer

Interventions

Administration of Enoxaparin(2000IU twice a day, POD1-7) and mechanical thromboprophylaxis(POD1) mechanical thromboprophylaxis(POD1)

Sponsors

Gastroenterological Surgery 1 Hokkaido Univ. Graduated School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Postoperative function of the major organs(bone marrow, liver, kidneys, etc.) are held sufficiently; patients that meet the following criteria (hemoglobin : 9.5g/dl or more, ALT and AST: 2.5 times less than the normal value of the facility, total bilirubin: 3.0mg/dl or less, SpO2: 90% or more).

Exclusion criteria

Exclusion criteria: 1)Patients with heparin-induced thrombocytopenia or patients with a history of hypersensitivity of to heparin or related substances(HIT). 2)Patients with acute bacterial endocarditis 3)Patients with severe to moderate renal dysfunction(creatinine clearance below 50mL/min). 4)Patients with severe liver failure. 5)Low-weight patients (weight less than 40kg) 6)Women who may possibly be pregnant or are pregnant. 7)Patients receiving antiplatelet drugs (such as clopidogrel or aspirin) or anticoagulant drugs (warfarin etc.) affecting hemostasis preoperatively. 8)Patients with venous thromboembolic disease was observed within one year prior to surgery of this study or the patient with clinical signs or merger of deep vein thrombosis. 9)Ppatients with contraindications of iodinated contrast agent. 10)Patients who have indwelling central venous catheter. 11)Patients treated with progesterone and estrogen formulation within 4 weeks before administration. 12)Patients receiving radiation therapy or systemic cancer chemotherapy within two weeks before the administration. 13)Patients is determined inappropriate as a test target by principal investigator.

Design outcomes

Primary

MeasureTime frame
Incidence of VTE.

Countries

Japan

Contacts

Public ContactHirofumi Kamachi

Hokkaido Univ. Graduated School of Medicine Gastroenterological Surgery 1

hkamachi@db3.so-net.ne.jp011-706-5927

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026